Study on the Effect of Conbercept Intravitreal Injection for Proliferative Diabetic Retinopathy at Perioperative Period
Abstract: AIM: To compare the effects of pars plana vitrectomy (PPV) with or without conbercept intravitreal injection of proliferative diabetic retinopathy (PDR). METHODS: 23 patients (26 eyes) with PDR in our hospital from December 2014 to December 2015 were recruited, and were randomly divided into two groups. 11 cases (12 eyes) in control group were received single vitrectomy. In ex-perimental group, 12 cases (14 eyes) were injected by drug therapy of conbercept and received vitrectomy. In the postoperative follow-up of 1 year, the general situation of operation and thera-peutic effect between the two groups were analyzed. RESULTS: The average operation time, bleeding during operation of the experimental group were lower than that of the control group; they were significantly different. There was no statistically significant difference between two groups on CMT & BCVA before operation, but the experimental group had better effect than control group at 4mo. CONCLUSION: Intravitreal injection of conbercept before vitrectomy can decrease the operation time, reduce active neovascularization, minimize the incidence of intraoperative haemorrhage and iatrogenic retinal breaks incidence, alleviate macular edema and improve BCVA of patients in the treatment of PDR.
文章引用: 于梦丹 , 姜 涛 , 姜 靖 , 王云霄 , 李 廷 , 孙 哲 , 郑盼盼 , 全 威 (2017) 增殖性糖尿病视网膜病变围手术期玻璃体腔内注射康柏西普的疗效研究。 眼科学， 6， 12-18. doi: 10.12677/HJO.2017.61003
 乌云, 其其格, 杨亮单. 纯玻璃体切除术与联合超声乳化术治疗增生性糖尿病视网膜病变的疗效对比[J]. 中国实用医药, 2014(14): 3-6.
 张祺, 冯劼, 程旭康, 等. 严重PDR玻璃体切除术和全视网膜光凝的视力对比[J]. 国际眼科杂志, 2012, 12(11): 2204-2205.
 卢海. 增殖性糖尿病视网膜病变眼内组织纤溶酶原激活物及其抑制物的表达与VEGF表达的相关性研究[J]. 国际眼科杂志, 2007, 6(7): 501.
 卢海, 张惠荣. 生长因子诱导的血管内皮细胞增殖作用的研究[J]. 眼科研究, 2001, 19(4): 297-300.
 Sone, H., Deo, B.K. and Kumagai, A.K. (2000) Enhancement of Glucose Transport by Vascular Endothelial Growth Factor in Retinal Endothelial Cells. Investigative Ophthalmology & Visual Science, 41, 1876-1884.
Chen, E. and Park, C.H. (2006) Use of Intravitreal Bevacizumab as Apreoperative Adjunct for Tractional Retinal Detachment Repair in Severe Proliferative Diabetic Retinopathy. Retina, 26, 699-700.
Ip, M.S., Domalpally, A., Hopkins, J.J., et al. (2012) Long-Term Effects of Ranibizumab on Diabetic Retinopathy Severity and Progression. Arch Ophthalmol, 130, 1145-1152.
 Van Geest, R.J., Lesnik-Oberstein, S.Y., Tan, H.S., et al. (2012) A Shift in the Balance of Vascular Endothelial Growth Factor and Connective Tissue Growth Factor by Bevacizumab Causes the Anglo Fibrotic Switch in Proliferative Diabetic Retinopathy. British Journal of Ophthalmology, 96, 587-590.
 El-Sabagh, H.A., Abdelghaffar, W., Labib, A.M., et al. (2011) Preoperative Intravitreal Bevacizumab Use as an Adjuvant to Diabetic Vitrectomy: Histopathologic Findings and Clinical Implication. Ophthalmology, 118, 636-641.
Gupta, A., Bansal, R., Gupta, V., et al. (2012) Six-Month Visual Outcome after Pars Plana Vitrectomy in Proliferative Diabetic Retinopathy with or without a Single Preoperative Injection of Intravitreal Bevacizumab. International Ophthalmology, 32, 135-144.
Ikeda, T., Sato, K., Katano, T., et al. (2000) Visual Acuity Following Pars Plana Itrectomy for Diabet Cystoidsmaculr Edema and Detached Posterior Hyaloids. Retina, 20, 220-222.
Ikeda, T., Sato, K., Katano, T., et al. (1999) Vitrectomy for Cystoid Macular Oedema with Attached Posterior Hyaloidmembrane in Patients with Diabetes. British Journal of Ophthalmology, 83, 12-14.
Ozaki, H., Hayashi, H., Vinores, S.A., et al. (1997) Intravitreal Sustained Re-lease of VEGF Causes Retinal Neovascularization in Rabbits and Breakdown of the Blood-Retinal Barrier in Rabbits and Primates. Experimental Eye Research, 64, 505-517.
 Funatsu, H., Noma, H., Mimura, T., et al. (2009) Association of Vitreous Inflammatory Factors with Diabetic Macular Edema. Ophthalmology, 116, 73-79.
 程琳. ETDRS标准对数视力表视力测试[J]. 中华试验眼科杂志, 2011, 29(6): 574-575.